- Home
- WIMI vs CUE Comparison
WIMI vs CUE Comparison
Compare WIMI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIMI | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 27.1M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WIMI | CUE |
|---|---|---|
| Price | $1.88 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 44.3K | ★ 316.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.26 | $0.23 |
| 52 Week High | $7.26 | $1.12 |
Technical Indicators
Market Signals| Indicator | WIMI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 47.64 |
| Support Level | N/A | $0.29 |
| Resistance Level | $3.06 | $0.36 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 60.00 | 73.35 |
Price Performance
Historical ComparisonAbout WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.